Ocugen Reports 54.3% Revenue Increase but Wider Net Loss in Q3 2025

Ocugen, Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $1.75 million, a 54.3% increase from $1.14 million in the same period last year. The rise in revenue was primarily attributed to collaborative arrangement revenue, which increased by $616,000 due to a reassessment of co-development services provided to a business partner. However, the company also reported a net loss of $20.05 million for the quarter, compared to a loss of $12.97 million in the prior year, reflecting a significant increase in operating expenses.

Total operating expenses for the quarter reached $19.38 million, up from $14.39 million in the previous year, marking a 34.7% increase. This rise was driven by higher research and development costs, which increased by $3.04 million to $11.15 million, largely due to increased clinical activities related to the Phase 3 trial for OCU400 and the Phase 2/3 trial for OCU410ST. General and administrative expenses also rose by $1.95 million, primarily due to professional services fees associated with business development.

In terms of strategic developments, Ocugen entered a licensing agreement with Kwangdong Pharmaceutical for the development and commercialization of its OCU400 product candidate in South Korea, receiving an initial non-refundable fee of $0.8 million. The company also faced a setback with the termination of a merger agreement with Carisma Therapeutics due to insufficient funding commitments. Despite these challenges, Ocugen continues to pursue new strategic partnerships and investment opportunities.

Operationally, Ocugen's cash position as of September 30, 2025, was $32.57 million, a decrease from $58.51 million at the end of 2024. The company has incurred significant losses since its inception, with an accumulated deficit of $390.36 million. The company’s management indicated that the current cash reserves are insufficient to fund operations for the next 12 months, necessitating additional funding through various means, including public and private placements of equity or debt.

Looking ahead, Ocugen remains focused on advancing its product candidates, including OCU400 and OCU410ST, with plans to file for regulatory approvals in the coming years. However, the company acknowledges the inherent risks and uncertainties in the biotechnology sector, particularly regarding the successful commercialization of its products and the need for substantial additional funding to support ongoing operations and development efforts.